BackSarepta Therapeutics Overview
Sarepta Therapeutics Inc

Sarepta Therapeutics Target Price

Analysts' average 12-month price target for Sarepta Therapeutics is $24.

Get informed when a big investor buys or sells

+ Follow

Share Price

$17.5

Average Target Price

$24.0037.1% upside

3 analysts in the last 4 months

High: $27 | Low: $20

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-27Morgan Stanley$2542.9% upsideOpen
2026-07-09Piper Sandler$2014.3% upsideOpen
2026-07-08Wolfe Research$2754.3% upsideOpen
2026-05-15Evercore ISI$198.6% upsideOpen
2026-03-26Deutsche Bank$1420% downsideOpen
2026-03-26Wedbush$35100% upsideOpen
2026-03-12Mizuho SecuritiesUy Ear$3177.1% upsideOpen
2026-03-03Loop Capital MarketsIlya Zubkov$2542.9% upsideOpen
2026-03-03JefferiesAndrew Tsai$3071.4% upsideOpen
2026-01-27Robert W. Baird$2225.7% upsideOpen
2025-12-09Wedbush$3282.9% upsideOpen
2025-11-25Bernstein$2014.3% upsideOpen
2025-11-05Barclays$2014.3% upsideOpen
2025-11-05Mizuho SecuritiesUy Ear$2648.6% upsideOpen
2025-11-04Robert W. BairdBrian Skorney$1514.3% downsideOpen
2025-10-30Piper SandlerBiren Amin$168.6% downsideOpen
2025-09-09Leerink PartnersJoseph Schwartz$1514.3% downsideOpen
2025-08-21Barclays$2225.7% upsideOpen
2025-08-15Deutsche BankDavid Hoang$1231.4% downsideOpen
2025-07-22BarclaysGena Wang$182.9% upsideOpen
2025-07-21BMO CapitalKostas Biliouris$50185.7% upsideOpen
2025-07-19Leerink PartnersJoseph Schwartz$1042.9% downsideOpen
2025-06-25H.C. Wainwright$1042.9% downsideOpen
2025-06-17Wells FargoYanan Zhu$75328.6% upsideOpen
2025-06-16Cantor FitzgeraldKristen Kluska$2014.3% upsideOpen
2025-06-15BMO CapitalKostas Biliouris$70300% upsideOpen
2025-04-21Piper Sandler$110528.6% upsideOpen
2024-11-27Piper SandlerBiren Amin$182940% upsideOpen
2024-11-27NeedhamGil Blum$2021054.3% upsideOpen
2024-11-07Robert W. BairdBrian Skorney$1931002.9% upsideOpen
2024-11-07Cantor FitzgeraldKristen Kluska$167854.3% upsideOpen
2024-10-21JefferiesAndrew Tsai$165842.9% upsideOpen
2024-08-08Evercore ISIGavin Clark-Gartner$179922.9% upsideOpen
2024-08-08Piper SandlerBiren Amin$2001042.9% upsideOpen
2024-08-08BarclaysGena Wang$2031060% upsideOpen
2024-08-08RBC CapitalBrian Abrahams$181934.3% upsideOpen
2024-07-29RBC CapitalBrian Abrahams$182940% upsideOpen
2024-06-27BMO CapitalKostas Biliouris$2001042.9% upsideOpen
2024-06-26Piper SandlerBiren Amin$2051071.4% upsideOpen
2024-06-24Evercore ISIGavin Clark-Gartner$185957.1% upsideOpen
2024-06-24Mizuho SecuritiesUy Ear$2001042.9% upsideOpen
2024-06-21Robert W. BairdBrian Skorney$2001042.9% upsideOpen
2024-06-13Robert W. BairdBrian Skorney$170871.4% upsideOpen
2024-06-13Piper SandlerBiren Amin$157797.1% upsideOpen
2024-06-13BarclaysGena Wang$185957.1% upsideOpen
2024-06-07BMO CapitalKostas Biliouris$170871.4% upsideOpen
2024-05-28RBC CapitalBrian Abrahams$142711.4% upsideOpen
2024-05-20RBC CapitalBrian Abrahams$157797.1% upsideOpen
2024-05-17Mizuho SecuritiesUy Ear$179922.9% upsideOpen
2024-05-14OppenheimerHartaj Singh$180928.6% upsideOpen

Sarepta Therapeutics (SRPT) FAQ

Sarepta Therapeutics posts a target price of $24. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $24 for SRPT means covering analysts, on average, see the stock 37.1% upside of $17.5 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for SRPT's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Sarepta Therapeutics's other metric pages and overview cover the third.

Judging Sarepta Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $24 here, then scan peer and history charts to see if the gap is persistent.